Table 1

Summary of trial characteristics

TrialNORAM22CYCAZAREM19MEPEX20CYCLOPS21IMPROVE23RITUXVAS24
Number of patients10015513714915644
Disease severityCr<150 µmol/L, no critical organ diseaseCr<500 µmol/L, no life threatening diseaseCr>500 µmol/L or requiring dialysisGeneralised disease with renal involvement but Cr<500 µmol/LAny disease severityRenal involvement
TreatmentInduction: methotrexate versus cyclophosphamideMaintenance: cyclophosphamide versus azathioprineInduction: adjunctive treatment for severe glomerulonephritisInduction: daily oral versus pulsed cyclophosphamideMaintenance: mycophenolate mofetil versus azathioprineInduction: Rituximab versus cyclophosphamide
Date1995–20001995–20001995–20022000–20042002–20092006–2007
Follow-up18 months (treatment for 12 months)18 months12 months18 monthsMedian of 39 months12 months
LTFUYesYesYesYesNoNo

  • Cr, creatinine; LTFU, long-term follow-up questionnaire.